Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Shannon Benesh

Nurse Practitioner, Adult Health New York, NY Nurse Practitioner

NPI 1881239192 CMS profile 11199479

622 W 168Th St, New York, NY 10032

Open in the dashboard

General payments

$5,562

39 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Benesh of New York, NY is reported in the CMS Open Payments database as having received $5,562 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,573 14
2024 General $3,634 17
2023 General $323 6
2022 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Benesh
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Shannon Benesh were reported at $1,573. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Shannon Benesh Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $138 $43–$438 $132
2022 $32 $165 $54–$494 $149
2023 $323 $178 $61–$549 $160
2024 $3,634 $186 $62–$575 $164
2025 $1,573 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $5,168 31 payments
  2. United Therapeutics Corporation $336 6 payments
  3. Novo Nordisk Inc $34 1 payment
  4. Eisai Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $3,413 3 payments
  2. Food and Beverage $1,257 32 payments
  3. Travel and Lodging $892 4 payments
Products named General payments · program years 2022–2025
  1. OFEV Respiratory $3,800 14 payments
  2. OFEV Respiratory $98 5 payments
  3. Steen Solution $78 1 payment
  4. TYVASO $78 2 payments
  5. JASCAYD $57 2 payments
  6. Wegovy $34 1 payment
  7. Leqembi $24 1 payment
  8. JARDIANCE $16 1 payment
  9. STIOLTO RESPIMAT $16 1 payment
  10. SPIRIVA RESPIMAT $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,361

Median for Nurse Practitioner: 389

Drug cost

$6,315,956

Median for Nurse Practitioner: $21,885

Branded share of claims

71.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 392 $5,182,377
Tyvaso Dpi Treprostinil Brand 30 $681,471
Pirfenidone Generic 77 $292,375
Mycophenolic Acid Mycophenolate Sodium Brand 30 $34,600
Breo Ellipta Fluticasone/Vilanterol Brand 57 $27,919
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $27,398
Spiriva Respimat Tiotropium Bromide Brand 24 $17,378
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 24 $15,494
Mycophenolate Mofetil Generic 85 $12,505
Arnuity Ellipta Fluticasone Furoate Brand 33 $8,876

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$33,293

Medicare's payments for the services billed

Medicare patients

148

Average age 72

Services billed

256

85 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 53%
COPD 39%
Ischemic heart disease 36%
Diabetes 34%
Depression 27%
Osteoporosis 22%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $2,631
$2,631 392 —
Wegovy
  • Novo Nordisk Inc $34
$34 — —
Leqembi
  • Eisai Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record